99455-06-8

Usage

Uses

Used in Chemical Synthesis:
5-BROMO-2-METHOXYQUINOLINE is used as a building block in chemical synthesis for the preparation of various bioactive molecules. Its unique structure allows it to be a versatile component in creating new compounds with potential applications in different fields.
Used in Pharmaceutical Research:
In pharmaceutical research, 5-BROMO-2-METHOXYQUINOLINE is utilized as a key intermediate for the development of new drugs. Its presence in the molecular structure can contribute to the desired pharmacological properties, making it an important compound in the search for novel therapeutic agents.
Used in Antimalarial Applications:
5-BROMO-2-METHOXYQUINOLINE has been studied for its potential antimalarial properties. It may be used as a starting point for the development of new antimalarial drugs, which could help combat the growing issue of drug-resistant malaria strains.
Used in Antimicrobial Applications:
5-BROMO-2-METHOXYQUINOLINE has also been investigated for its antimicrobial properties, suggesting that it could be used in the development of new antibiotics or antifungal agents. This could be particularly useful in addressing the increasing problem of antibiotic resistance.
Used in Drug Discovery and Development:
Due to its unique structural and chemical properties, 5-BROMO-2-METHOXYQUINOLINE is considered a useful tool in drug discovery and development. Researchers can use 5-BROMO-2-METHOXYQUINOLINE to explore its potential in creating new drugs with various therapeutic applications.

Upstream product

• 124-41-4 sodium methylate 
• 99455-13-7 5-bromo-2-chloroquinoline 
• 99465-09-5 5-bromoquinolin-2(1H)-one 
• 99465-18-6 (E)-N-(3-bromophenyl)-3-ethoxypropenamide 
• 591-19-5 m-Bromoaniline 
• 67-56-1 methanol 
• 846038-45-7 5-bromoquinoline N-oxide 

Relevant academic research and scientific papers

Enantioselective Copper-Catalyzed Alkynylation of Benzylic C-H Bonds via Radical Relay

The first enantioselective alkynylation of benzylic C-H bonds via copper-catalyzed radical relay has been established herein, which provides an easy access to structurally diverse benzylic alkynes in good yields with excellent enantioselectivities. A key step for the asymmetric copper-catalyzed radical relay process is the enantioselective capture of a benzylic radical with chiral (Box)CuII-alkynyl species. In addition, the reaction displays good functional group tolerance, broad substrate scope, and mild conditions. The enantioenriched alkynylation products can be readily transformed into highly valuable synthons, such as chiral terminal alkynes, allenes, alkenes, and carboxylic acids. More importantly, our methodology can be applied to the synthesis of bioactive molecule AMG 837.

BMP INHIBITORS AND METHODS OF USE THEREOF

The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation. These compounds may also be used to reduce circulating levels of ApoB-100 or LDL and treat or prevent acquired or congenital hypercholesterolemia or hyperlipoproteinemia; diseases, disorders, or syndromes associated with defects in lipid absorption or metabolism; or diseases, disorders, or syndromes caused by hyperlipidemia.

GLUCAGON RECEPTOR ANTAGONIST COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE

Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

2(1H)-Quinolinones with cardiac stimulant activity. 1. Synthesis and biological activities of (six-membered heteroaryl)-substituted derivatives

A series of (six-membered heteroaryl)-substituted 2(1H)-quinolinones was synthesized, and structure-activity relationships for cardiac stimulant activity were determined. Most compounds were prepared by acidic hydrolyisis of a heteroaryl-2-methoxyquinoline obtained by palladium-catalyzed cross-coupling methodology. Direct reaction of a pyridinylzinc reagent with a 6-haloquinolinone also proved successful. In anesthetized dogs, 6-pyridin-3-yl-2(1H)-quinolinone (3; 50 μg/kg) displayed greater inotropic activity (percentage increase in dP/dt max) than positional isomers, and potency was maintained with either mono- or di- alkylpyridinyl substituents. Introduction of a 4- or 7- methyl group into 3 reduced inotropic activity, whereas the 8-isomer proved to be the most potent member of the series. Compound 26 and the 2,6-dimethylpyridinyl analogue (27 were approximately 6 and 3 times more potent than milrinone. Several quinolinones displayed positive inotropic activity (decrease in QA interval) in conscious dogs after oral administration (1 mg/kg), and 26, 27 were again the most potent members of the series. Compound 27 (0.25, 0.5, 1.0 mg/kg po) demonstrated dose-related cardiac stimulant activity, which was maintained for at least 4 h. No changes in heart rate were observed. Compounds 3, 4, 26, and 27 also selectively stimulated the force of contraction, rather than heart rate, in the dog heart-lung preparation. For a 50% increase in dP/dt max with 27, heart rate changed by less than 10 beats/min. In norepinephrine contracted rabbit femoral artery and saphenous vein, 27 produced dose related (5 x 10-7 to 5 x 10-4 M) vasorelaxant activity. The combined cardiac stimulant and vasodilator properties displayed by 27, coupled with a lack of effect on heart rate, should be beneficial for the treatment of congestive heart failure.